( BW)(DIATOS) Diatos Strengthens Management Team with the Appointment
of New Chief Medical Officer and New Chief Sales & Marketing Officer

    Business Editors/Health/Medical Writers

    PARIS--(BUSINESS WIRE)--Oct. 9, 2006--Diatos SA, an international
biopharmaceutical company focusing on the research, development and
commercialization of targeted anti-cancer drugs, announces that Dr
Jamal Gasmi has been appointed Chief Medical Officer and Dr James
Cowburn has been appointed Chief Sales & Marketing Officer, both
reporting to the President & Chief Executive Officer, Dr John
Tchelingerian.

    Dr Gasmi has 20 years experience in clinical development in
oncology/haematology acquired both in the pharmaceutical industry and
academic cancer research centers. Before joining Diatos, Dr Gasmi was
International Medical Leader, Oncology, at Roche in Basel,
Switzerland, where he oversaw the development of Herceptin(R)
(trastuzumab), providing medical input in the development and
implementation of strategic plans. Prior to that, he spent eight years
at the Pierre Fabre laboratory (France) in a similar position with
full responsibility for the corporate clinical development and
implementation of Navelbine(R) (vinorelbine) worldwide. Between 1990
and 1998, Dr Gasmi was a consultant in medical oncology at the
Paris-based Institut Gustave Roussy and at Hopitaux de Paris. In this
role, Dr Gasmi led teams of oncologists, was head of teaching,
training and clinical research activities and was also involved as the
investigator or co-investigator in multi centric, multinational
clinical trials from Phase I to Phase III in non-small cell lung,
breast, colorectal, ovary, head & neck cancers as well as lymphoma.
Upon completing his medical training at Universite Paris VI, Dr Gasmi
had begun his career in France in internal medicine, then in cancer
research teams at Institut Gustave Roussy (1986-1989) where he
coordinated cancer research projects and thereafter at London Medical
Hospital College, UK, until 1990. Dr Gasmi is a medical doctor and
also has a postgraduate degree in immunology/medical oncology, a
Masters degree in pharmaco-oncology as well as a European board
certification in medical oncology. He has been an active member of
ASCO and ESMO for over 16 years and is a reviewer of various
scientific journals and the author/co-author of more than 65
scientific publications.

    Dr Cowburn has over 16 years experience gained in several key
sales and marketing management positions in oncology pharmaceuticals
at Schering Plough, NeXstar (now part of Gilead) and Roche. He was
most recently the Global Product Director Oncology at Zeneus Pharma
(now part of Cephalon Inc., USA), UK, responsible for the global
re-launch and development of Myocet(R) (liposomal doxorubicin) in
breast cancer, ovarian cancer, NHL and other tumors. Dr Cowburn
started his career by holding several oncology sales & marketing
positions at Roche and Schering-Plough between 1990 and 1997. Dr
Cowburn was then employed by NeXstar (Gilead) until 2003 in a variety
of roles in strategic oncology marketing, business development and
affiliate marketing and sales across their haemato-oncology portfolio,
including DaunoXome(R) which was acquired by Diatos from Gilead in
March 2006. Dr Cowburn was also responsible for introducing Gilead's
antiviral products into the UK as well as building and growing the
company's marketing, training, pricing, distribution and reimbursement
programs in readiness for entry into the HIV market. After leaving
Gilead, Dr Cowburn was a consultant to Roche leading a special primary
care project team to revitalize the sales of a lead brand.

    John Tchelingerian, President and CEO of Diatos, commented: "These
two key appointments will add substantial medical and
commercialization expertise to Diatos at the right moment to execute
our ambitious plans for the upcoming marketing of our product
DaunoXome(R) and moving forward the clinical development of our lead
product candidates DTS-301 and DTS-201. I am pleased to welcome Jamal
and James to Diatos and trust their expertise and experience will be
an important asset as we continue to grow and reinforce our
oncology-focused business."

    Notes to Editors:

    About Diatos

    Diatos is a biopharmaceutical company dedicated to the research,
development and commercialization of innovative anti-cancer drugs with
enhanced tumor targeting or improved biodistribution. Diatos is
expanding its portfolio of drug candidates with new compounds that
utilize its Vectocell(R) delivery technology or its Tumor-Selective
Prodrug (TSP) technology as well as with in-licensed candidate and
marketed cancer therapies. Diatos is headquartered in Paris, France
and operates subsidiaries in Belgium and the United States of America.

    For more information on Diatos, please visit www.diatos.com.

    The Diatos logo and Vectocell(R) are registered trademarks of
Diatos SA.

    About Diatos' Portfolio

    -- DaunoXome(R), a liposomal formulation of widely used cancer
drug daunorubicin, improves the biodistribution of daunorubicin and
fosters its sustained release in the blood, which potentially allows
the administration of higher doses than with non-liposomal
formulations. DaunoXome is marketed in Kaposi's sarcoma and under
review in acute leukaemia in Europe.

    -- DTS-301, a paclitaxel formulation in polymer gel ReGel(R),
releases paclitaxel, a widely used cancer drug, directly to the tumor
site with a view to avoiding all systemic adverse side effects.
DTS-301 is in Phase II clinical studies.

    -- DTS-201, a doxorubicin prodrug, increases the concentration of
doxorubicin, a widely used cancer drug, at the tumor site by means of
a reactivation mechanism specific to the tumor environment. DTS-201
shares key biological principles with Diatos' TSP technology and is in
Phase I clinical studies.

    -- DTS-108 is a prodrug of SN-38, the active metabolite of
widely-used cancer drug irinotecan, and is based on Diatos'
Vectocell(R) technology. DTS-108 aims to increase the efficacy of
SN-38 while reducing the toxic effects of irinotecan. DTS-108 is in
preclinical development.


-0-
*T
General enquiries
Dr John Tchelingerian, PhD, President & CEO
c/o Virginie Leplat, HR and Administrative Manager & Personal
Assistant to the CEO
Tel.: +33 (0)1 53 80 93 80, Email: vleplat@diatos.com
&
c/o Guillaume Dussert, Communications & Marketing Project Manager
Tel.: +33-(0)1 53 80 93 83, Email: gdussert@diatos.com
www.diatos.com
*T

    --30--CT/ny*

    CONTACT: Northbank Communications
             Katja Stout, +44 (0)20 7886 8150
             k.stout@northbankcommunications.com
             or
             Justine Lamond, +44 (0)20 7886 8150
             j.lamond@northbankcommunications.com